Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Ruxolitinib vs best available therapy

Progression‐free survival (PSF) · Patients with treating MF

Ruxolitinib showed no clear difference in progression Free Survival (number of patients who had progression at compared with best available therapy (low certainty).

1 finding from 1 review

Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
HR 0.81 [0.47, 1.39]
1 study · 219 participants
Low